Request Consultation
The globe is broadly employing evidence-based, software-driven interventions to mitigate, manage, or treat medical illnesses & disorders, which is defined as digital therapeutics (DTx). The latest DTx has a key scope in diverse concerns, such as depression, anxiety disorders, PTSD, & substance use disorders through Cognitive Behavioral Therapy (CBT) modules & adaptive digital tracking.
Apart from this, sophisticated digital therapeutics foster assistance for diabetes, hypertension, asthma, & COPD by monitoring physiological markers, prompting medication adherence, & anticipating symptom spikes.
- Elevating Management, Engagement & Progressions Fuels the Comprehensive Breakthroughs of Digital Therapeutics (DTx)
- A major catalyst is the growing instances of diabetes, obesity, & cardiovascular disease, which need long-term management. In this case, DTx offers a massive, affordable approach to monitor patients at home & boost clinical outcomes.
- On the other hand, many government & private health insurers are increasingly establishing structured reimbursement codes & coverage policies, providing patients subsidized or fully covered access to clinical software, which impacts the demand.
- ubstantial development of smart devices, wearables, & continuous health sensors is enabling real-time patient tracking & seamless interaction among caregivers & patients.
Rapid Expansion of the Digital Therapeutics Market Accelerates Global Healthcare Transformation
The global digital therapeutics market size is calculated at USD 9.84 billion in 2025, grows to USD 12.58 billion in 2026, and is projected to reach around USD 114.37 billion by 2035. The market is expanding at a CAGR of 27.8% between 2026 and 2035. The global digital therapeutics market is growing rapidly due to rising chronic diseases, virtual healthcare adoption, and AI-powered medical software advancements. Increasing smartphone usage, wearable integration, and supportive regulatory frameworks are accelerating market expansion. According to Towards Healthcare’s Digital Therapeutics Market Insights, demand for personalized digital care solutions continues rising globally.
What are the Prospective Technological Opportunities of the Digital Therapeutics (DTx)?
- In the coming era, leading firms will focus on machine learning algorithms, which support the analysis of individual patient metrics to actively adjust therapeutic complexity or intensity in real-time.
- However, extensive DTx solutions will push the application of VR integrated with biofeedback for pain management, neurological rehabilitation, & psychological exposure therapies.
- Emerging wearable biosensors & smartwatches will record cortisol levels, galvanic skin response, or heart rate changes, triggering immediate DTx treatments in response to physiological stress.
Top Funding Provisions of Leading Players in Digital Therapeutics in 2026
| Leading Players | Funding Provisions |
| Click Therapeutics (April 2026) | Raised $50 million in Series D funding from Boehringer Ingelheim to push the commercialization of its CT-155 prescription digital therapeutic. |
| brainjo GmbH (April 2026) |
Secured €2 million in seed funding to speed up the progression of virtual reality-based digital therapeutics, with an initial emphasis on treating children with ADHD. |
| Big Health (February 2026) |
Raised a planned funding of $23.7M to surge access to its FDA-authorized reimbursable solutions, i.e. SleepioRx for insomnia disorder & DaylightRx for generalized anxiety disorder. |
Regional Spotlight: Coupled with Recent Significant Efforts
In the last year, North America registered dominance in the digital therapeutics, as it has a well-established healthcare infrastructure, wider adoption of digital health technologies, & favourable regulatory landscapes. More specifically, the Canadian government has reinforced telehealth accessibility with prominent investments, which cover perfect unification of DTx into these platforms, improving treatment adherence & widening care to underserved & rural areas.
Alongside, the U.S. was a huge contributor to DTx, while the FDA has dynamically included the intersection of software, sensors, & AI in patient care. Also, a draft was published on AI-assisted regulatory decision-making, whereas over 100 digital diagnostics & 140 prescription digital therapeutics became commercially available for remote patient use.
Rigorous Regulatory Frameworks of APAC Countries Spurs the Booming Developments in DTx
Asia Pacific is predicted to expand rapidly in the digital therapeutics, due to the accelerating incidence of chronic issues, higher use of smartphones, & breakthroughs in mobile health technologies. In South Korea, the Digital Medical Products Act (DMPA) has been evolving specialized legal categories for software as a medical device (SaMD) & drug-digital combination products. Numerous health systems in countries, such as Singapore, are incorporating AI-enabled decision tools into national health infrastructures to control geriatric populations & resource scarcity.
Furthermore, an impressive step has been taken by the National Medical Products Administration (NMPA) in releasing the Guiding Principles for Classification and Definition of Rehabilitation Digital Therapy Software Products. This further makes the first official regulatory landscape particularly targeting digital therapies.
Latest Roll Outs in Digital Therapeutics in 2026
- In April 2026, Healthcare Triangle, Inc. launched ZoraNex, an AI-powered digital self-care therapy platform designed under its wholly owned subsidiary, QuantumNexis Inc.
- In March 2026, GAIA & Daiichi Sankyo Europe partnered to unveil the latest digital therapeutic for cardiovascular care in Europe.
- In January 2026, Ultrahuman & Click Therapeutics collaborated to introduce the Migraine PowerPlug by combining the proprietary technology behind Click’s CT-132 directly into the Ultrahuman platform.
Immersive Groundbreakings of Top Five Firms Involved in Digital Therapeutics
| Top Companies | Groundbreakings |
| Omada Health | This has explored clinically validated, virtual-first care programs for diabetes, hypertension, & musculoskeletal (MSK) issues. This mainly combines smart devices with tailored behavioral coaching to propel lifestyle changes. |
| Click Therapeutics | Specifically, this has introduced software-based prescription treatments (PDTs) for substantial depressive disorder, migraine, & smoking cessation. |
| Sword Health | A firm fosters innovations in AI-driven physical therapy by leveraging proprietary wearable sensors & AI to offer patients real-time feedback during home-based exercises. |
| Welldoc | This is a developer of BlueStar, an innovative FDA-cleared digital therapeutic for diabetes. |
| Biofourmis | A player is executing integration of wearable biosensors with AI-enabled software algorithms to estimate severe medical events, like heart failure exacerbations, before they occur. |
Conclusion
Globally rising prevalence of various chronic diseases, including diabetes, obesity, and heart diseases, is driving the need for advanced management systems, while DTx provides inexpensive and robust remote care, with enhanced outcomes. Day by day, the leaders are pushing advancements in the integration of wearable sensors and AI solutions, specifically in depression, PTSD, anxiety disorders & substance use disorders. Besides this, a key step of different governments includes rigorous modifications or publications in regulatory frameworks, which widely support the global adoption & demand for DTx.
About the Experts
Aditi Shivarkar
Aditi leads as Vice President at Towards Healthcare and brings over 15 years of experience in healthcare research, innovation, and strategy. She works closely with data from across the healthcare sector and turns it into clear direction that companies can actually use. Her work covers pharmaceuticals, medical devices, and digital health. She helps businesses understand where the market is going and how to respond with confidence. Aditi focuses on practical thinking, strong decision-making, and delivering real results that make a difference.
Aman Singh
Aman Singh brings over 13 years of experience in healthcare research and consulting. He studies global healthcare trends and keeps a close eye on areas like biotech, AI in healthcare, and new treatment approaches. At Towards Healthcare, he leads the research team and makes sure the work stays accurate, useful, and easy to understand. Aman breaks down complex changes in the industry and helps businesses make smart, informed decisions.
Piyush Pawar
Piyush Pawar works as Senior Manager for Sales and Business Growth at Towards Healthcare, with more than 10 years of experience in the healthcare space. He works directly with clients and helps them find the right research for their needs. He makes sure clients understand the insights and know how to use them in their business. Piyush builds strong relationships and focuses on helping companies grow by turning research into clear, practical action.
